Development of a universal cell- and humoral-mediated influenza vaccine for humans, targeting the NP and HA proteins of the virus, facilitated by the development of an automated immuno-monitoring test.

Rapid diagnostic solution for bacterial and fungal infections responsible for sepsis, and their resistance to antimicrobials.

Registration of a self-replicating RNA vaccine platform targeting the swine influenza virus and development of organoid platforms enabling the adaptation of a vaccine to a zoonotic pandemic strain in less than 100 days.

National tool for detecting and monitoring epidemics and pandemics of respiratory viruses.

Innovative sugar-based anti-infective agents that mimic the natural receptors of pathogens, helping to prevent viral resistance and minimize side effects.

New generation of broad-spectrum antivirals that inhibit cellular mechanisms essential for virus replication and have an anti-inflammatory effect.

Breakthrough immunoassay technology, based on bioluminescence and developed over more than a decade of research, revolutionizing biological diagnostics with ultra-sensitive and ultra-fast results.

New-generation muco-excipient platform designed to optimize the intranasal administration of complex biomolecules, whether recombinant proteins, mRNA, or other innovative formats.

Innovative and rapid antibiotic susceptibility testing (antibiogram) using patented fluorogenic biotracer technology, capable of drastically reducing the time required to obtain results.